Enovis Corporation

Enovis Corporation

ENOVยทNYSE

$21.56

-1.7%
HealthcareMedical - Devices

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

At a Glance

Live Snapshot
Market Cap$1.24B
EPS-20.8600
P/E Ratio-1.03
Earnings Date08/06/2026
3Y+44.0%
5Y+101.0%
10Y-38.0%
3Y+8811.0%
5Y-2879.0%
10Y-1025.0%
3Y-489.0%
5Y-28.0%
10Y-12.0%
Enovis Corporation

Enovis Corporation Profit Bridge

ENOV ยท NYSE
Revenue2.25B
Cost of Goods Sold (902.79M)
Gross Profit1.35B
Operating Expenses (2.53B)
Operating Income-1.18B
Interest Expense (34.82M)
Other Income/Expense22.29M
Pretax Income-1.16B
Income Tax (22.29M)
Net Income-1.18B
Net Income
-1.18B

Profitability Analysis

Gross Margin

59.8%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

-52.6%

Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.

Net Profit Margin

-52.7%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

Enovis Corporation Income Statement

ENOV โ€ข NYSE

Enovis Corporation Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
REVENUE
2.2B
2.1B
1.7B
1.6B
1.4B
1.1B
3.3B
3.7B
3.3B
3.6B
4B
4.6B
4.2B
3.9B
693.4M
542M
525M
604.9M
506.3M
393.6M
GROSS PROFIT
(902.8M)
(926.9M)
(716.4M)
(693.7M)
(648.5M)
(517.1M)
(1.9B)
(2.5B)
(2.3B)
(2.5B)
(2.7B)
(3.1B)
(2.9B)
(2.8B)
(453.3M)
(350.6M)
(339.2M)
(387.7M)
(330.7M)
(256.8M)
1.3B
1.2B
990.8M
869.4M
777.7M
603.6M
1.4B
1.1B
1B
1.1B
1.3B
1.5B
1.3B
1.2B
240.1M
191.4M
185.8M
217.2M
175.6M
136.8M
OPERATING INCOME
(2.5B)
(2B)
(1.1B)
(940.6M)
(840.5M)
(669.8M)
(1.2B)
(818.2M)
(732.3M)
(825.2M)
(906M)
(1B)
(861M)
(895.5M)
(150.5M)
(125.6M)
(117.4M)
(200.5M)
(52.3M)
(117.3M)
(1.1B)
(939.4M)
(830.3M)
(772.9M)
(665.8M)
(515.5M)
(1.1B)
(818.2M)
(732.3M)
(825.2M)
(906M)
(1B)
(861M)
(895.5M)
(144.8M)
(119.4M)
(113.7M)
(125.2M)
(98.5M)
(113.9M)
(120.3M)
(91.3M)
(75.3M)
(60.8M)
(49.1M)
(34.3M)
(0.0)
(34.2M)
(42.9M)
(39.3M)
(41.5M)
(43M)
(27.4M)
(19.4M)
(5.7M)
(6.2M)
(5.9M)
(5.9M)
(4.2M)
(3.3M)
-1.2B
-775.7M
-65.7M
-71.2M
-62.8M
-66.2M
203.6M
236.9M
29.2M
238M
284.6M
409.6M
406.4M
140M
25.9M
34.4M
38.5M
16.7M
123.3M
19.5M
PRE-TAX INCOME
(34.8M)
(57.1M)
(19.7M)
(25M)
(29.1M)
(52.8M)
(119.5M)
(49.1M)
(40.1M)
(30M)
(47.7M)
(51.3M)
(103.6M)
(91.6M)
(5.9M)
(6.7M)
(7.2M)
(11.8M)
(0.0)
(0.0)
-34.8M
-57.1M
-19.7M
-24.8M
-29.1M
-52.8M
-119.5M
-49.1M
-40.1M
-30.3M
-47.5M
-51.3M
-103.6M
-91.6M
-5.9M
-6.7M
-7.2M
-11.8M
0.0
0.0
(1.3B)
(925.8M)
(150.9M)
(106.8M)
(125.6M)
(120.1M)
(65.3M)
(39K)
-46.9M
-8.2M
-21.1M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-50.3M
(0.0)
22.3M
-47.2M
-1.4M
69.1M
-59M
-52.8M
-153.1M
-59.2M
-147.6M
-30.3M
-28.7M
-51.3M
-103.6M
-91.6M
-5.9M
-6.7M
-6M
-11.8M
-19.2M
-14.2M
-1.2B
-822.9M
-67.1M
-2.1M
-121.8M
-119M
50.5M
182.8M
-12M
208M
236.9M
358.2M
302.8M
48.4M
20M
27.7M
31.2M
4.9M
104M
5.4M
NET INCOME
(22.3M)
(4.5M)
-13.3M
(36.1M)
-19.5M
-44.6M
(31.6M)
-21K
(42.6M)
(62.8M)
(49.7M)
-62M
(93.7M)
(90.7M)
(15.4M)
(11.5M)
(9.5M)
(5.4M)
(39.1M)
(3.9M)
-1.2B
-825.5M
-33.3M
-13.3M
71.7M
42.6M
-527.6M
140.2M
151.1M
128.1M
167.7M
392.1M
178.6M
-64.4M
4.6M
16.2M
21.7M
-571K
64.9M
94K

SEC Filings

ENOV - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 19, 2026
May 19, 2026
2026
10-Q

10-Q 2026 Q2

Q2

May 07, 2026
April 03, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 06, 2026
April 06, 2026
2026
10-K

10-K 2025 FY

FY

February 26, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 26, 2026
February 26, 2026
2026
8-K

8-K 2026

N/A

January 12, 2026
January 12, 2026
2026
8-K

8-K 2025

N/A

December 15, 2025
December 10, 2025
2025
8-K

8-K 2025

N/A

December 10, 2025
December 08, 2025
2025
8-K

8-K 2025

N/A

November 14, 2025
November 07, 2025
2025
Showing 1 to 10 of 330 filings